NCCRP1
gene geneOn this page
Also known as LOC342897NCCRP-1FBXO50
Summary
NCCRP1 (NCCRP1, F-box associated domain containing, HGNC:33739) is a protein-coding gene on chromosome 19q13.2, encoding F-box only protein 50 (Q6ZVX7). Promotes cell proliferation.
Predicted to contribute to ubiquitin protein ligase activity. Involved in positive regulation of cell population proliferation. Located in cytosol.
Source: NCBI Gene 342897 — RefSeq curated summary.
At a glance
- Clinical variants (ClinVar): 60 total
- MANE Select transcript:
NM_001001414
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:33739 |
| Approved symbol | NCCRP1 |
| Name | NCCRP1, F-box associated domain containing |
| Location | 19q13.2 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | LOC342897, NCCRP-1, FBXO50 |
| Ensembl gene | ENSG00000188505 |
| Ensembl biotype | protein_coding |
| OMIM | 615901 |
| Entrez | 342897 |
Gene structure
Transcript identifiers
Ensembl transcripts: 2 — 2 protein_coding
ENST00000339852, ENST00000855675
RefSeq mRNA: 1 — MANE Select: NM_001001414
NM_001001414
CCDS: CCDS12529
Canonical transcript exons
ENST00000339852 — 6 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001364171 | 39199170 | 39199265 |
| ENSE00001372877 | 39198053 | 39198115 |
| ENSE00001373664 | 39196964 | 39197319 |
| ENSE00001374775 | 39200346 | 39200484 |
| ENSE00001374852 | 39200616 | 39201884 |
| ENSE00001389639 | 39198202 | 39198253 |
Expression profiles
Bgee: expression breadth ubiquitous, 115 present calls, max score 99.56.
FANTOM5 (CAGE): breadth broad, TPM avg 4.9297 / max 1564.3523, expressed in 314 samples.
FANTOM5 promoters (2 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 175688 | 4.0548 | 284 |
| 175687 | 0.8749 | 211 |
Top tissues by expression
131 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| lower esophagus mucosa | UBERON:0035834 | 99.56 | gold quality |
| esophagus mucosa | UBERON:0002469 | 97.82 | gold quality |
| skin of leg | UBERON:0001511 | 97.57 | gold quality |
| zone of skin | UBERON:0000014 | 97.56 | gold quality |
| skin of abdomen | UBERON:0001416 | 97.55 | gold quality |
| vagina | UBERON:0000996 | 87.69 | gold quality |
| body of pancreas | UBERON:0001150 | 77.06 | gold quality |
| esophagus | UBERON:0001043 | 76.62 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 73.75 | gold quality |
| tonsil | UBERON:0002372 | 73.75 | gold quality |
| minor salivary gland | UBERON:0001830 | 73.69 | gold quality |
| saliva-secreting gland | UBERON:0001044 | 72.38 | gold quality |
| pancreas | UBERON:0001264 | 71.15 | gold quality |
| adult mammalian kidney | UBERON:0000082 | 64.33 | gold quality |
| placenta | UBERON:0001987 | 63.83 | gold quality |
| ectocervix | UBERON:0012249 | 62.72 | gold quality |
| vermiform appendix | UBERON:0001154 | 62.51 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 62.02 | gold quality |
| uterine cervix | UBERON:0000002 | 61.70 | gold quality |
| kidney | UBERON:0002113 | 61.10 | gold quality |
| urinary bladder | UBERON:0001255 | 60.83 | gold quality |
| islet of Langerhans | UBERON:0000006 | 60.38 | gold quality |
| cortex of kidney | UBERON:0001225 | 58.83 | gold quality |
| duodenum | UBERON:0002114 | 58.80 | gold quality |
| metanephros cortex | UBERON:0010533 | 57.29 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 56.82 | gold quality |
| rectum | UBERON:0001052 | 56.63 | gold quality |
| left uterine tube | UBERON:0001303 | 55.80 | gold quality |
| thoracic mammary gland | UBERON:0005200 | 55.46 | gold quality |
| lymph node | UBERON:0000029 | 55.21 | gold quality |
Single-cell (SCXA)
Detected in 3 experiment(s), a significant marker in 2.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-MTAB-7381 | yes | 825.43 |
| E-ANND-3 | yes | 4.07 |
| E-MTAB-5061 | no | 3.53 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
51 targeting NCCRP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-4283 | 100.00 | 66.42 | 2097 |
| HSA-MIR-6851-5P | 100.00 | 65.63 | 1294 |
| HSA-MIR-3689D | 100.00 | 66.14 | 1181 |
| HSA-MIR-3613-3P | 100.00 | 76.36 | 7965 |
| HSA-MIR-4455 | 100.00 | 65.48 | 1587 |
| HSA-MIR-6127 | 100.00 | 66.76 | 2188 |
| HSA-MIR-4768-5P | 100.00 | 69.49 | 2861 |
| HSA-MIR-6833-3P | 100.00 | 70.63 | 3197 |
| HSA-MIR-4510 | 100.00 | 66.60 | 2050 |
| HSA-MIR-6129 | 100.00 | 66.46 | 2080 |
| HSA-MIR-6130 | 100.00 | 66.69 | 2012 |
| HSA-MIR-6133 | 100.00 | 66.48 | 2064 |
| HSA-MIR-371B-5P | 99.99 | 75.34 | 4759 |
| HSA-MIR-373-5P | 99.98 | 75.36 | 4753 |
| HSA-MIR-616-5P | 99.98 | 75.58 | 4775 |
| HSA-MIR-23A-3P | 99.95 | 74.24 | 3163 |
| HSA-MIR-23B-3P | 99.95 | 74.24 | 3163 |
| HSA-MIR-23C | 99.95 | 73.92 | 3192 |
| HSA-MIR-4648 | 99.91 | 67.00 | 710 |
| HSA-MIR-765 | 99.84 | 68.24 | 2442 |
| HSA-MIR-11181-3P | 99.75 | 66.38 | 2205 |
| HSA-MIR-3175 | 99.65 | 66.30 | 2031 |
| HSA-MIR-6134 | 99.63 | 65.68 | 1537 |
| HSA-MIR-4276 | 99.56 | 67.66 | 2514 |
| HSA-MIR-4489 | 99.50 | 65.56 | 785 |
| HSA-MIR-4441 | 99.49 | 66.56 | 3216 |
| HSA-MIR-661 | 99.09 | 65.94 | 2062 |
| HSA-MIR-7854-3P | 99.08 | 66.26 | 1117 |
| HSA-MIR-4270 | 99.02 | 66.26 | 1987 |
| HSA-MIR-6889-3P | 98.84 | 67.35 | 1198 |
Literature-anchored findings (GeneRIF, showing 2)
- to characterize human NCCRP1 and to elucidate its relationship to carbonic anhydrase IX (PMID:22087255)
- High FBXO50 expression is associated with Gastric Cancer. (PMID:28560594)
Cross-species orthologs
3 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | nccrp1 | ENSDARG00000035326 |
| mus_musculus | Nccrp1 | ENSMUSG00000047586 |
| rattus_norvegicus | Nccrp1 | ENSRNOG00000054506 |
Paralogs (5): FBXO2 (ENSG00000116661), FBXO6 (ENSG00000116663), FBXO44 (ENSG00000132879), FBXO27 (ENSG00000161243), FBXO17 (ENSG00000269190)
Protein
Protein identifiers
F-box only protein 50 — Q6ZVX7 (reviewed: Q6ZVX7)
Alternative names: NCC receptor protein 1 homolog, Non-specific cytotoxic cell receptor protein 1 homolog
All UniProt accessions (1): Q6ZVX7
UniProt curated annotations — full annotation on UniProt →
Function. Promotes cell proliferation.
Subcellular location. Cytoplasm.
Tissue specificity. Expressed in the esophagus, oral cavity, skin, tongue and reproductive organs.
RefSeq proteins (1): NP_001001414* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR007397 | F-box-assoc_dom | Domain |
| IPR008979 | Galactose-bd-like_sf | Homologous_superfamily |
| IPR039752 | F-box_only | Family |
Pfam: PF04300
UniProt features (7 total): modified residue 3, chain 1, domain 1, region of interest 1, compositionally biased region 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q6ZVX7-F1 | 86.68 | 0.69 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (3): 31, 37, 49
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 83 (showing top):
GOBP_RESPONSE_TO_NITROGEN_COMPOUND, BENPORATH_ES_WITH_H3K27ME3, GOBP_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_CATABOLIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, GOBP_SCF_DEPENDENT_PROTEASOMAL_UBIQUITIN_DEPENDENT_PROTEIN_CATABOLIC_PROCESS, GOBP_PROTEASOMAL_PROTEIN_CATABOLIC_PROCESS, GOBP_ERAD_PATHWAY, GOBP_PROTEIN_CATABOLIC_PROCESS, GOBP_GLYCOPROTEIN_METABOLIC_PROCESS, GOCC_SCF_UBIQUITIN_LIGASE_COMPLEX, GOCC_TRANSFERASE_COMPLEX, GOBP_PROTEOLYSIS, GOCC_CULLIN_RING_UBIQUITIN_LIGASE_COMPLEX
GO Biological Process (4): glycoprotein catabolic process (GO:0006516), positive regulation of cell population proliferation (GO:0008284), SCF-dependent proteasomal ubiquitin-dependent protein catabolic process (GO:0031146), ERAD pathway (GO:0036503)
GO Molecular Function (2): protein binding (GO:0005515), ubiquitin protein ligase activity (GO:0061630)
GO Cellular Component (4): cytoplasm (GO:0005737), cytosol (GO:0005829), SCF ubiquitin ligase complex (GO:0019005), extracellular exosome (GO:0070062)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cellular anatomical structure | 2 |
| glycoprotein metabolic process | 1 |
| protein catabolic process | 1 |
| carbohydrate derivative catabolic process | 1 |
| cell population proliferation | 1 |
| regulation of cell population proliferation | 1 |
| positive regulation of cellular process | 1 |
| proteasome-mediated ubiquitin-dependent protein catabolic process | 1 |
| proteasomal protein catabolic process | 1 |
| response to endoplasmic reticulum stress | 1 |
| response to chemical | 1 |
| binding | 1 |
| ubiquitin-protein transferase activity | 1 |
| ubiquitin-like protein ligase activity | 1 |
| intracellular anatomical structure | 1 |
| cytoplasm | 1 |
| cullin-RING ubiquitin ligase complex | 1 |
| extracellular vesicle | 1 |
Protein interactions and networks
STRING
368 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| NCCRP1 | MFAP4 | P55083 | 372 |
| NCCRP1 | FBXO34 | Q9NWN3 | 355 |
| NCCRP1 | SPRR2F | Q96RM1 | 348 |
| NCCRP1 | FBXO42 | Q6P3S6 | 330 |
| NCCRP1 | RWDD2B | P57060 | 313 |
| NCCRP1 | PRSS36 | Q5K4E3 | 311 |
| NCCRP1 | LY6G6F | Q5SQ64 | 310 |
| NCCRP1 | FBXO46 | Q6PJ61 | 300 |
| NCCRP1 | CD8A | P01732 | 297 |
| NCCRP1 | DHRS1 | Q96LJ7 | 285 |
| NCCRP1 | SACK1C | Q9BQN1 | 283 |
| NCCRP1 | SLCO5A1 | Q9H2Y9 | 275 |
| NCCRP1 | FBXW12 | Q6X9E4 | 272 |
| NCCRP1 | A2ML1 | A8K2U0 | 269 |
| NCCRP1 | RHCG | Q9UBD6 | 263 |
IntAct
116 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| FANCG | FANCA | psi-mi:“MI:0914”(association) | 0.960 |
| POT1 | TERF2 | psi-mi:“MI:0914”(association) | 0.890 |
| ASH2L | KMT2D | psi-mi:“MI:0914”(association) | 0.890 |
| RIN1 | NRAS | psi-mi:“MI:0914”(association) | 0.840 |
| POLR2L | RCCD1 | psi-mi:“MI:0914”(association) | 0.640 |
| CCNC | MED19 | psi-mi:“MI:0914”(association) | 0.640 |
| ALDH3A1 | RCCD1 | psi-mi:“MI:0914”(association) | 0.640 |
| CFAP298 | PEX7 | psi-mi:“MI:0914”(association) | 0.620 |
| NCCRP1 | DDI1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| FES | DSP | psi-mi:“MI:0914”(association) | 0.560 |
| ZSCAN12 | A2ML1 | psi-mi:“MI:0914”(association) | 0.530 |
| FTH1 | A2ML1 | psi-mi:“MI:0914”(association) | 0.530 |
| TBC1D22B | A2ML1 | psi-mi:“MI:0914”(association) | 0.530 |
| CCDC51 | TGM5 | psi-mi:“MI:0914”(association) | 0.530 |
| DPPA4 | ALOX12B | psi-mi:“MI:0914”(association) | 0.530 |
| MRPL38 | DUSP14 | psi-mi:“MI:0914”(association) | 0.530 |
| UCP2 | CST4 | psi-mi:“MI:0914”(association) | 0.530 |
| STK16 | FLG | psi-mi:“MI:0914”(association) | 0.530 |
| ZIC1 | CTSV | psi-mi:“MI:0914”(association) | 0.530 |
| CLINT1 | PIK3C2A | psi-mi:“MI:0914”(association) | 0.530 |
| POMK | CLGN | psi-mi:“MI:0914”(association) | 0.530 |
| NRAS | ESYT2 | psi-mi:“MI:2364”(proximity) | 0.480 |
| ESR1 | psi-mi:“MI:0914”(association) | 0.460 | |
| NCCRP1 | CFTR | psi-mi:“MI:0915”(physical association) | 0.370 |
| STK4 | ANXA2P2 | psi-mi:“MI:0914”(association) | 0.350 |
| WTAP | DDX39A | psi-mi:“MI:0914”(association) | 0.350 |
| LRRK2 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (124): NCCRP1 (Affinity Capture-MS), NCCRP1 (Affinity Capture-MS), NCCRP1 (Affinity Capture-MS), NCCRP1 (Affinity Capture-MS), NCCRP1 (Affinity Capture-MS), NCCRP1 (Affinity Capture-MS), NCCRP1 (Affinity Capture-MS), NCCRP1 (Affinity Capture-MS), NCCRP1 (Affinity Capture-MS), NCCRP1 (Affinity Capture-MS), NCCRP1 (Affinity Capture-MS), NCCRP1 (Affinity Capture-MS), NCCRP1 (Affinity Capture-MS), NCCRP1 (Affinity Capture-MS), NCCRP1 (Affinity Capture-MS)
ESM2 similar proteins: A0A8I5KY20, A2A9Q0, A9JSM3, C9JI98, D4A2Q0, D4ABX8, E7ERA6, F1SAM7, F2Z333, O94819, P0C7J6, P0CG25, P13224, P56400, Q04785, Q0GA42, Q17QZ8, Q1RMK9, Q2MJR0, Q2WF71, Q504Y2, Q50LG9, Q5RJI4, Q6IEE6, Q6IEE7, Q6IQX7, Q6P6N5, Q6PJG9, Q6UKI2, Q6UX72, Q6ZMC9, Q6ZT52, Q6ZVX7, Q7Z6J2, Q80XU8, Q86UD0, Q86VR8, Q8BQB4, Q8IZ52, Q8QZV0
Diamond homologs: G3X9C2, Q17QK6, Q3SX24, Q568V3, Q6AY27, Q6DIA9, Q6ZVX7, Q80UW2, Q8NI29, Q923V4, Q96EF6, Q9H4M3, Q9N0C8, Q9NRD1, Q9QZM8, Q9UK22, Q8BK26, Q9QZN4
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
60 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 55 |
| Likely benign | 1 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
712 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 19:39197258:G:GT | donor_gain | 1.0000 |
| 19:39197319:GGTG:G | donor_loss | 1.0000 |
| 19:39197320:G:C | donor_loss | 1.0000 |
| 19:39197345:G:GT | donor_gain | 1.0000 |
| 19:39198051:AGG:A | acceptor_loss | 1.0000 |
| 19:39198112:CTGGG:C | donor_loss | 1.0000 |
| 19:39198114:GG:G | donor_gain | 1.0000 |
| 19:39198115:GG:G | donor_gain | 1.0000 |
| 19:39198116:G:GA | donor_loss | 1.0000 |
| 19:39198116:G:GG | donor_gain | 1.0000 |
| 19:39198117:TAAG:T | donor_loss | 1.0000 |
| 19:39198197:T:A | acceptor_gain | 1.0000 |
| 19:39198198:GCA:G | acceptor_loss | 1.0000 |
| 19:39198199:CAG:C | acceptor_loss | 1.0000 |
| 19:39198200:A:AG | acceptor_gain | 1.0000 |
| 19:39198200:AG:A | acceptor_gain | 1.0000 |
| 19:39198201:G:GG | acceptor_gain | 1.0000 |
| 19:39198201:GG:G | acceptor_gain | 1.0000 |
| 19:39198201:GGC:G | acceptor_gain | 1.0000 |
| 19:39198201:GGCA:G | acceptor_gain | 1.0000 |
| 19:39198201:GGCAA:G | acceptor_gain | 1.0000 |
| 19:39198250:AAAGG:A | donor_loss | 1.0000 |
| 19:39198251:AAGG:A | donor_loss | 1.0000 |
| 19:39198252:AGG:A | donor_loss | 1.0000 |
| 19:39198253:GGTG:G | donor_loss | 1.0000 |
| 19:39198254:G:GG | donor_gain | 1.0000 |
| 19:39199168:A:AG | acceptor_gain | 1.0000 |
| 19:39199168:AGCT:A | acceptor_gain | 1.0000 |
| 19:39199168:AGCTG:A | acceptor_gain | 1.0000 |
| 19:39199169:G:GA | acceptor_gain | 1.0000 |
AlphaMissense
1729 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 19:39199182:G:C | K155N | 0.995 |
| 19:39199182:G:T | K155N | 0.995 |
| 19:39200629:T:C | F234S | 0.995 |
| 19:39200665:T:C | F246S | 0.995 |
| 19:39197294:C:A | N104K | 0.994 |
| 19:39197294:C:G | N104K | 0.994 |
| 19:39199256:T:A | V180D | 0.994 |
| 19:39199261:G:C | D182H | 0.993 |
| 19:39198216:T:A | W139R | 0.992 |
| 19:39198216:T:C | W139R | 0.992 |
| 19:39199171:T:A | W152R | 0.992 |
| 19:39199171:T:C | W152R | 0.992 |
| 19:39199199:T:A | L161H | 0.991 |
| 19:39200476:T:A | W227R | 0.991 |
| 19:39200476:T:C | W227R | 0.991 |
| 19:39200478:G:C | W227C | 0.991 |
| 19:39200478:G:T | W227C | 0.991 |
| 19:39200734:T:A | V269E | 0.991 |
| 19:39199173:G:C | W152C | 0.990 |
| 19:39199173:G:T | W152C | 0.990 |
| 19:39199250:T:A | I178N | 0.990 |
| 19:39200655:T:C | F243L | 0.990 |
| 19:39200657:T:A | F243L | 0.990 |
| 19:39200657:T:G | F243L | 0.990 |
| 19:39200722:C:T | T265I | 0.990 |
| 19:39200728:C:T | S267F | 0.990 |
| 19:39198207:T:C | F136L | 0.989 |
| 19:39198209:C:A | F136L | 0.989 |
| 19:39198209:C:G | F136L | 0.989 |
| 19:39200628:T:C | F234L | 0.989 |
dbSNP variants (sampled 300 via entrez): RS1000471949 (19:39196368 G>A), RS1000754098 (19:39197814 T>G), RS1000823063 (19:39196564 G>A), RS1001197160 (19:39195802 G>A), RS1001207343 (19:39197547 T>C), RS1001228504 (19:39195524 A>G), RS1001816369 (19:39201374 G>A), RS1002234034 (19:39196925 TC>T), RS1002478150 (19:39198944 C>A), RS1002677519 (19:39200031 C>G), RS1004458430 (19:39198547 C>T), RS1004580354 (19:39200227 G>T), RS1004799931 (19:39200006 G>A,C,T), RS1006253594 (19:39201521 G>A), RS1006273657 (19:39195584 T>G)
Disease associations
OMIM: gene MIM:615901 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
0 associations (top):
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
30 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Particulate Matter | increases abundance, increases expression, decreases expression | 3 |
| Air Pollutants | decreases expression, increases abundance | 2 |
| Tobacco Smoke Pollution | affects expression, increases expression | 2 |
| Valproic Acid | increases expression, affects expression | 2 |
| Cadmium Chloride | decreases expression, increases abundance, increases expression | 2 |
| sodium arsenate | increases abundance, decreases expression | 1 |
| pyrogallol 1,3-dimethyl ether | affects cotreatment, decreases expression | 1 |
| ethyl-p-hydroxybenzoate | increases expression | 1 |
| sulforaphane | decreases expression | 1 |
| butyraldehyde | increases expression | 1 |
| S-(1,2-dichlorovinyl)cysteine | decreases reaction, increases expression | 1 |
| abrine | increases expression | 1 |
| licochalcone B | decreases expression | 1 |
| prothioconazole | increases expression | 1 |
| Resveratrol | affects cotreatment, decreases expression | 1 |
| Sunitinib | decreases expression | 1 |
| Acetaminophen | decreases expression | 1 |
| Arsenic | decreases expression, increases abundance | 1 |
| Benzo(a)pyrene | increases methylation, affects methylation | 1 |
| Cadmium | decreases expression, increases abundance | 1 |
| Cisplatin | decreases expression | 1 |
| Diethylhexyl Phthalate | increases expression | 1 |
| Estradiol | affects cotreatment, decreases expression | 1 |
| Furaldehyde | affects cotreatment, increases expression | 1 |
| Lead | decreases expression | 1 |
| Lipopolysaccharides | increases expression, decreases reaction | 1 |
| Plant Extracts | decreases expression, affects cotreatment | 1 |
| Smoke | increases abundance, decreases expression | 1 |
| Sodium Chloride | affects cotreatment, increases expression, decreases expression | 1 |
| Lactic Acid | decreases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.